dc.contributor.author
Ferrer, Pili
dc.contributor.author
Sabaté, Mònica
dc.contributor.author
Ballarín, Elena
dc.contributor.author
Fortuny, Joan
dc.contributor.author
Rottenkolber, Marietta
dc.contributor.author
Schmiedl, Sven
dc.contributor.author
Laporte Rosselló, Joan-Ramón
dc.contributor.author
Ibáñez, Luisa
dc.contributor.author
Fundació Institut Català de Farmacologia
dc.identifier
https://ddd.uab.cat/record/185465
dc.identifier
urn:10.1186/s40064-015-1398-4
dc.identifier
urn:oai:ddd.uab.cat:185465
dc.identifier
urn:pmid:26543747
dc.identifier
urn:pmcid:PMC4628133
dc.identifier
urn:pmc-uid:4628133
dc.identifier
urn:oai:egreta.uab.cat:publications/84c99658-9604-4e2c-b92c-3da46e7c8c23
dc.identifier
urn:recercauab:ARE-90630
dc.identifier
urn:scopus_id:84944460346
dc.identifier
urn:wos_id:000364860100003
dc.identifier
urn:oai:pubmedcentral.nih.gov:4628133
dc.description.abstract
The research leading to these results was conducted as part of the PROTECT Consortium (Pharmacoepidemiological Research on Outcomes of Thera-peutics by a European ConsorTium, http://www.imi-protect.eu) which is apublic-private partnership coordinated by the European Medicines Agency.The PROTECT project has received support from the Innovative Medicines Initiative Join Undertaking [IMIJU] (http://www.imi.europa.eu) under Grant Agreement no 115004, resources of which arecomposed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries andAssociations (EFPIA)companies'in kind contribution. The views expressed are those of the authors only.
dc.description.abstract
The online version of this article (doi:10.1186/s40064-015-1398-4) contains supplementary material, which is available to authorized users.
dc.format
application/pdf
dc.relation
SpringerPlus ; Vol. 4 (october 2015)
dc.rights
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.subject
Drug utilisation
dc.subject
Cross-national comparison
dc.subject
Defined daily doses
dc.subject
Prescription rates
dc.subject
Antibacterials
dc.title
Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007-2010
